KLK3
Prostate-specific antigen
Protein Summary
Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum. Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
- ENST00000326003
- ENSP00000314151
- ENSG00000142515
- ENST00000360617
- ENSP00000353829
- ENST00000593997
- ENSP00000472907
- ENST00000595952
- ENSP00000471155
- APS
- APS
- PSA
- hK3
- KLK2A1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 1 | ||
transcription factor perturbation | 0.97 | ||
chemical | 0.94 | ||
PubMedID | 0.94 | ||
disease | 0.6 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 29583.17 (req: < 5)
Gene RIFs: 369 (req: <= 3)
Antibodies: 2256 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 29583.17 (req: >= 5)
Gene RIFs: 369 (req: > 3)
Antibodies: 2256 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 26
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 3